Abstract
A 62-year-old female dialysis patient with chronic glomerulonephritis had been receiving hemodialysis therapy for 32 years. In 1985 she underwent a parathyroidectomy for secondary hyperparathyroidism (HPT); however, her parathyroid hormone (PTH) levels gradually increased. Her serum calcium level ranged from 9.0 to 10.0 mg/dL, which caused difficulties in performing vitamin D injection therapy. No parathyroid glands were seen by echography or scintigraphy. On 31 March 2008 her intact PTH (iPTH) level was 895 pg/mL so treatment with cinacalcet 25 mg/day was started. After 3 months her iPTH level decreased to 269 pg/mL and her hemoglobin level increased from 9.3 to 12.9 g/dL. In some cases of severe HPT, anemia improves after parathyroidectomy; however, in this case, cinacalcet improved not only secondary HPT but also anemia.
Similar content being viewed by others
References
Barbour GL. Effect of parathyroidectomy on anemia in chronic renal failure. Arch Intern Med. 1979;139:889–91.
Goicoechea M, Gomez-Campdera F, Polo JR, Tejedor A, Ruiz MA, Vazquez I, et al. Secondary hyperparathyroidism as cause of resistance to treatment with erythropoietin: effect of parathyroidectomy. Clin Nephrol. 1996;45:420–1.
Coen G, Calabria S, Bellinghieri G, Pecchini F, Conte F, Chiappini MG, et al. Parathyroidectomy in chronic renal failure: short- and long-term results on parathyroid function, blood pressure and anemia. Nephron. 2001;88:149–55.
Goicoechea M, Vazquez MI, Ruiz MA, Gomez-Campdera F, Perez-Garcia R, Valderrabano F. Intravenous calcitriol improves anaemia and reduces the need for erythropoietin in haemodialysis patients. Nephron. 1998;78:23–7.
Nemeth EF, Steffey ME, Hammerland LG, Hung BC, Van Wagenen BC, DelMar EG, et al. Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc Natl Acad Sci USA. 1998;95:4040–5.
Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350:1516–25.
Rao DS, Shih MS, Mohini R. Effect of serum parathyroid hormone and bone marrow fibrosis on the response to erythropoietin in uremia. N Engl J Med. 1993;328:171–5.
Johnson DW, Pollock CA, Macdougall IC. Erythropoiesis-stimulating agent hyporesponsiveness. Nephrology. 2007;12:321–30.
Kanbay M, Perazella MA, Kasapoglu B, Koroglu M, Covic A. Erythropoiesis stimulatory agent-resistant anemia in dialysis patients: review of causes and management. Blood Purif. 2010;29:1–12.
Urena P, Eckardt KU, Sarfati E, Zingraff J, Zins B, Roullet JB, et al. Serum erythropoietin and erythropoiesis in primary and secondary hyperparathyroidism: effect of parathyroidectomy. Nephron. 1991;59:384–93.
Fukagawa M, Yumita S, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, et al. Cinacalcet (KRN1493) effectively decreases the serum intact PTH level with favorable control of the serum phosphorus and calcium levels in Japanese dialysis patients. Nephrol Dial Transplant. 2008;23:328–35.
Shigematsu T, Akizawa T, Uchida E, Tsukamoto Y, Iwasaki M, Koshikawa S. Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am J Nephrol. 2009;29:230–6.
Urena P, Hruby M, Ferreira A, Ang KS, de Vernejoul MC. Plasma total versus bone alkaline phosphatase as markers of bone turnover in hemodialysis patients. J Am Soc Nephrol. 1996;7:506–12.
Hutchison AJ, Whitehouse RW, Boulton HF, Adams JE, Mawer EB, Freemont TJ, et al. Correlation of bone histology with parathyroid hormone, vitamin D3, and radiology in end-stage renal disease. Kidney Int. 1993;44:1071–7.
Fukagawa M, Kitaoka M, Inazawa T, Kurokawa K. Imaging of the parathyroid in chronic renal failure: diagnostic and therapeutic aspects. Curr Opin Nephrol Hypertens. 1997;6:349–55.
Nagano N. Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol Ther. 2006;109:339–65.
Lien YH, Silva AL, Whittman D. Effects of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol Dial Transplant. 2005;20:1232–7.
Acknowledgments
This paper was supported in part by grant from The Kidney Foundation, Japan (JKFB09-46).
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Oshiro, Y., Tanaka, H. & Okimoto, N. A patient undergoing chronic dialysis whose renal anemia was successfully corrected by treatment with cinacalcet. Clin Exp Nephrol 15, 607–610 (2011). https://doi.org/10.1007/s10157-011-0433-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10157-011-0433-1